Latest Funding News

Platinum Asia Investments has finalized its restructuring scheme, exchanging shares for units in the Platinum Asia Fund Complex ETF and declaring a substantial special dividend for shareholders.

Butn Limited has reported a notable turnaround in its financial results for the year ended June 2025, with revenue growth and a sharp reduction in net loss, though dividends remain off the table.

Abacus Group (ASX – ABG) reported a strong turnaround in FY25 with a net profit of $26.9 million and a 35.6% rise in revenue, maintaining steady distributions while navigating a strategic stake in Abacus Storage King amid an acquisition proposal.

Strickland Metals has announced the discovery of a new high-grade copper-gold zone at its 5.3Moz AuEq Shanac Deposit in Serbia, revealing some of the highest copper grades ever recorded at the project. This breakthrough supports the company’s ambitious 50,000m drilling program and a targeted resource upgrade later this year.

American West Metals has completed critical development and permitting milestones at its Storm Copper Project in Nunavut, Canada, advancing its Pre-Feasibility Study and revealing promising drilling results that hint at resource expansion.

Vertex Minerals has commenced high-grade underground gold production at its Reward Mine, processing first ore through a new gravity-only plant and aiming to replace low-grade surface stockpiles with richer underground feed.

Love Group Global Ltd plans a shareholder vote on returning 3 cents per share, signalling confidence in its cash position and growth outlook.

Regal Partners Limited reported robust half-year results for 1H25, with funds under management reaching $17.7 billion and normalised net profit after tax hitting $44.8 million. The firm achieved record net inflows and maintained a strong balance sheet, signaling continued growth momentum.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.

Regal Partners reports a robust first half of 2025 with record net inflows and strong profit growth, underpinned by strategic expansion and a healthy balance sheet.

Regal Partners reports a 48% drop in statutory profit for H1 2025 despite growing funds under management to $17.7 billion, while strategically expanding into hotel real estate with the Mayfair Hotel acquisition.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.